|
1
|
Sander B, Larsen M, Moldow B and
Lund-Andersen H: Diabetic macular edema: passive and active
transport of fluorescein through the blood-retina barrier. Invest
Ophthalmol Vis Sci. 42:433–438. 2001.PubMed/NCBI
|
|
2
|
Qaum T, Xu Q, Joussen AM, et al:
VEGF-initiated blood-retinal barrier breakdown in early diabetes.
Invest Ophthalmol Vis Sci. 42:2408–2413. 2001.PubMed/NCBI
|
|
3
|
Mathews MK, Merges C, McLeod DS and Lutty
GA: Vascular endothelial growth factor and vascular permeability
changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci.
38:2729–2741. 1997.
|
|
4
|
Kernt M, Thiele S, Liegl RG, et al:
Axitinib modulates hypoxia-induced blood-retina barrier
permeability and expression of growth factors. Growth Factors.
30:49–61. 2012. View Article : Google Scholar
|
|
5
|
Wilson CA, Berkowitz BA, Sato Y, Ando N,
Handa JT and de Juan E Jr: Treatment with intravitreal steroid
reduces blood-retinal barrier breakdown due to retinal
photocoagulation. Arch Ophthalmol. 110:1155–1159. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McAllister IL, Vijayasekaran S, Chen SD
and Yu DY: Effect of triamcinolone acetonide on vascular
endothelial growth factor andoccludin levels in branch retinal vein
occlusion. Am J Ophthalmol. 147:838–846. 2009. View Article : Google Scholar
|
|
7
|
Jonas JB, Kreissig I and Degenring R:
Intraocular pressure after intravitreal injection of triamcinolone
acetonide. Br J Ophthalmol. 87:24–27. 2003. View Article : Google Scholar
|
|
8
|
Jonas JB, Degenring R, Vossmerbauemer U
and Kamppeter B: Frequency of cataract surgery after intravitreal
injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol.
15:462–464. 2005.PubMed/NCBI
|
|
9
|
Zhang L, Fu F, Zhang X, Zhu M, Wang T and
Fan H: Escin attenuates cognitive deficits and hippocampal injury
after transient global cerebral ischemia in mice via regulating
certain inflammatory genes. Neurochem Int. 57:119–127. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xin W, Zhang L, Fan H, Jiang N, Wang T and
Fu F: Escin attenuates acute lung injury induced by endotoxin in
mice. Eur J Pharm Sci. 42:73–80. 2011. View Article : Google Scholar
|
|
11
|
Wang T, Fu F, Zhang L, Han B, Zhu M and
Zhang X: Effects of escin on acute inflammation and the immune
system in mice. Pharmacol Rep. 61:697–704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Wang H, Fan H, et al: The potent
anti-inflammatory agent escin does not increase corticosterone
secretion and immune cell apoptosis in mice. Fitoterapia.
82:861–867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xin W, Zhang L, Sun F, et al: Escin exerts
synergistic anti-inflammatory effects with low doses of
glucocorticoids in vivo and in vitro. Phytomedicine. 18:272–277.
2011. View Article : Google Scholar
|
|
14
|
Gong YY, Yu SQ, Wang H, et al: Clinical
therapy of retinal vein occlusion with aescuven forte. Chin J New
Drugs Clin Rem. 12:965–968. 2005.
|
|
15
|
Wang W, Gong Y, Wang H, et al: Aescuven
forte in treating central serous chorioretinopathy. Chin J New
Drugs Clin Rem. 12:961–964. 2005.
|
|
16
|
Yuan YL and Wu LL: Clinical observation of
the central serous chorioretinopathy treated by aescinate sodium
tablets combined with argon laser. Guiding Journal of TCM and
Pharmacology. 15:58–59. 2009.(In Chinese).
|
|
17
|
Berenbaum MC: What is synergy? Pharmacol
Rev. 41:93–141. 1989.PubMed/NCBI
|
|
18
|
Furuse M, Hirase T, Itoh M, et al:
Occludin: a novel integral membrane protein localizing at tight
junctions. J Cell Biol. 123:1777–1788. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shibuya M: Vascular endothelial growth
factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for
angiogenesis. Angiogenesis. 9:225–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duh EJ, Yang HS, Suzuma I, et al: Pigment
epithelium-derived factor suppresses ischemia-induced retinal
neovascularization and VEGF-induced migration and growth. Invest
Ophthalmol Vis Sci. 43:821–829. 2002.PubMed/NCBI
|
|
21
|
Esser S, Wolburg K, Wolburg H, et al:
Vascular endothelial growth factor induces endothelial
fenestrations in vitro. J Cell Biol. 140:947–959. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Antonetti DA, Barber AJ, Hollinger LA,
Wolpert EB and Gardner TW: Vascular endothelial growth factor
induces rapid phosphorylation of tight junction proteins occludin
and zonula occluden-1. A potential mechanism for vascular
permeability in diabetic retinopathy and tumors. J Biol Chem.
274:23463–23467. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stewart MW: Corticosteroid use for
diabetic macular edema: old fad or new trend? Curr Diab Rep.
12:364–375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu L, Wu X, Geng J, Yuan Z and Chen L:
IVTA as adjunctive treatment to PRP and MPC for PDR and macular
edema: a meta-analysis. PLoS One. 7:e446832012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Felinski EA, Cox AE, Phillips BE and
Antonetti DA: Glucocorticoids induce transactivation of tight
junction genes occludin and claudin-5 in retinal endothelial cells
via a novel cis-element. Exp Eye Res. 86:867–878. 2008. View Article : Google Scholar : PubMed/NCBI
|
